Logo image of KOD

KODIAK SCIENCES INC (KOD) Stock Fundamental Analysis

NASDAQ:KOD - Nasdaq - US50015M1099 - Common Stock - Currency: USD

6.65  +0.08 (+1.14%)

Fundamental Rating

2

We assign a fundamental rating of 2 out of 10 to KOD. KOD was compared to 553 industry peers in the Biotechnology industry. While KOD seems to be doing ok healthwise, there are quite some concerns on its profitability. KOD does not seem to be growing, but still is valued expensively.


Dividend Valuation Growth Profitability Health

Quickly go to:

0

1. Profitability

1.1 Basic Checks

In the past year KOD has reported negative net income.
In the past year KOD has reported a negative cash flow from operations.
In the past 5 years KOD always reported negative net income.
KOD had a negative operating cash flow in each of the past 5 years.
KOD Yearly Net Income VS EBIT VS OCF VS FCFKOD Yearly Net Income VS EBIT VS OCF VS FCFYearly Net Income VS EBIT VS OCF VS FCF 2016 2017 2018 2019 2020 2021 2022 2023 2024 -100M -200M -300M

1.2 Ratios

With a Return On Assets value of -63.99%, KOD is not doing good in the industry: 61.12% of the companies in the same industry are doing better.
Looking at the Return On Equity, with a value of -175.14%, KOD is doing worse than 64.01% of the companies in the same industry.
Industry RankSector Rank
ROA -63.99%
ROE -175.14%
ROIC N/A
ROA(3y)-52.31%
ROA(5y)-39.78%
ROE(3y)-97.26%
ROE(5y)-69.5%
ROIC(3y)N/A
ROIC(5y)N/A
KOD Yearly ROA, ROE, ROICKOD Yearly ROA, ROE, ROICYearly ROA, ROE, ROIC 2016 2017 2018 2019 2020 2021 2022 2023 2024 0 200 -200 -400 -600 -800

1.3 Margins

KOD does not have Profit Margin and Operating Margin and Gross Margin available, so we won't be analyzing them here.
Industry RankSector Rank
OM N/A
PM (TTM) N/A
GM N/A
OM growth 3YN/A
OM growth 5YN/A
PM growth 3YN/A
PM growth 5YN/A
GM growth 3YN/A
GM growth 5YN/A
KOD Yearly Profit, Operating, Gross MarginsKOD Yearly Profit, Operating, Gross MarginsYearly Profit, Operating, Gross Margins 2016 2017 2018 2019 2020 2021 2022 2023 2024

More info and screens

6

2. Health

2.1 Basic Checks

Compared to 1 year ago, KOD has about the same amount of shares outstanding.
KOD has more shares outstanding than it did 5 years ago.
There is no outstanding debt for KOD. This means it has a Debt/Equity and Debt/FCF ratio of 0 and it is amongst the best of the sector and industry.
KOD Yearly Shares OutstandingKOD Yearly Shares OutstandingYearly Shares Outstanding 2016 2017 2018 2019 2020 2021 2022 2023 2024 10M 20M 30M 40M 50M
KOD Yearly Total Debt VS Total AssetsKOD Yearly Total Debt VS Total AssetsYearly Total Debt VS Total Assets 2016 2017 2018 2019 2020 2021 2022 2023 2024 200M 400M 600M 800M 1B

2.2 Solvency

KOD has an Altman-Z score of -7.16. This is a bad value and indicates that KOD is not financially healthy and even has some risk of bankruptcy.
KOD has a Altman-Z score of -7.16. This is in the lower half of the industry: KOD underperforms 66.91% of its industry peers.
KOD has no outstanding debt. Therefor its Debt/Equity and Debt/FCF ratios are 0 and belong to the best of the industry.
Industry RankSector Rank
Debt/Equity 0
Debt/FCF N/A
Altman-Z -7.16
ROIC/WACCN/A
WACCN/A
KOD Yearly LT Debt VS Equity VS FCFKOD Yearly LT Debt VS Equity VS FCFYearly LT Debt VS Equity VS FCF 2016 2017 2018 2019 2020 2021 2022 2023 2024 0 200M -200M 400M 600M 800M

2.3 Liquidity

A Current Ratio of 4.62 indicates that KOD has no problem at all paying its short term obligations.
KOD has a Current ratio of 4.62. This is comparable to the rest of the industry: KOD outperforms 49.91% of its industry peers.
A Quick Ratio of 4.62 indicates that KOD has no problem at all paying its short term obligations.
The Quick ratio of KOD (4.62) is comparable to the rest of the industry.
Industry RankSector Rank
Current Ratio 4.62
Quick Ratio 4.62
KOD Yearly Current Assets VS Current LiabilitesKOD Yearly Current Assets VS Current LiabilitesYearly Current Assets VS Current Liabilites 2016 2017 2018 2019 2020 2021 2022 2023 2024 200M 400M 600M 800M

More info and screens

1

3. Growth

3.1 Past

KOD shows a strong growth in Earnings Per Share. In the last year, the EPS has been growing by 18.06%, which is quite good.
EPS 1Y (TTM)18.06%
EPS 3YN/A
EPS 5YN/A
EPS Q2Q%-32.93%
Revenue 1Y (TTM)N/A
Revenue growth 3YN/A
Revenue growth 5YN/A
Sales Q2Q%N/A

3.2 Future

The Earnings Per Share is expected to grow by 8.89% on average over the next years. This is quite good.
No Revenue estimates are available, so we could not analyze the future revenue growth and evolution.
EPS Next Y-19.48%
EPS Next 2Y0.91%
EPS Next 3Y3.29%
EPS Next 5Y8.89%
Revenue Next YearN/A
Revenue Next 2YN/A
Revenue Next 3YN/A
Revenue Next 5YN/A

3.3 Evolution

No Revenue estimates are available, so we could not analyze the future revenue growth and evolution.
KOD Yearly Revenue VS EstimatesKOD Yearly Revenue VS EstimatesYearly Revenue VS Estimates 2019 2020 2027 2028 2029 2030 2031 2032 100M 200M 300M 400M 500M
KOD Yearly EPS VS EstimatesKOD Yearly EPS VS EstimatesYearly EPS VS Estimates 2018 2019 2020 2021 2022 2023 2024 2025 2026 2027 2028 2029 2030 2031 2032 0 -2 -4 -6

More info and screens

0

4. Valuation

4.1 Price/Earnings Ratio

KOD reported negative earnings for the last year, which makes the Price/Earnings Ratio negative.
Also next year KOD is expected to report negative earnings again, which makes the also the Forward Price/Earnings Ratio negative.
Industry RankSector Rank
PE N/A
Fwd PE N/A
KOD Price Earnings VS Forward Price EarningsKOD Price Earnings VS Forward Price Earnings ChartPrice Earnings - Forward Price Earnings PE FPE 0 20 40 60

4.2 Price Multiples

Industry RankSector Rank
P/FCF N/A
EV/EBITDA N/A
KOD Per share dataKOD EPS, Sales, OCF, FCF, BookValue per sharePer Share Data Per Share 0 1 -1 2 -2 -3

4.3 Compensation for Growth

PEG (NY)N/A
PEG (5Y)N/A
EPS Next 2Y0.91%
EPS Next 3Y3.29%

More info and screens

0

5. Dividend

5.1 Amount

No dividends for KOD!.
Industry RankSector Rank
Dividend Yield N/A

More info and screens

KODIAK SCIENCES INC

NASDAQ:KOD (8/1/2025, 8:00:02 PM)

6.65

+0.08 (+1.14%)

Chartmill FA Rating
GICS SectorHealth Care
GICS IndustryGroupPharmaceuticals, Biotechnology & Life Sciences
GICS IndustryBiotechnology
Earnings (Last)05-14 2025-05-14/amc
Earnings (Next)08-18 2025-08-18
Inst Owners82.14%
Inst Owner Change-0.17%
Ins Owners5.52%
Ins Owner Change0.03%
Market Cap350.85M
Analysts48.33
Price Target7.4 (11.28%)
Short Float %5%
Short Ratio5.58
Dividend
Industry RankSector Rank
Dividend Yield N/A
Yearly DividendN/A
Dividend Growth(5Y)N/A
DPN/A
Div Incr Years0
Div Non Decr Years0
Ex-DateN/A
Surprises & Revisions
EPS beat(2)1
Avg EPS beat(2)-7.37%
Min EPS beat(2)-20.72%
Max EPS beat(2)5.97%
EPS beat(4)3
Avg EPS beat(4)-1.09%
Min EPS beat(4)-20.72%
Max EPS beat(4)7.98%
EPS beat(8)5
Avg EPS beat(8)-4.46%
EPS beat(12)8
Avg EPS beat(12)-0.38%
EPS beat(16)8
Avg EPS beat(16)-4.19%
Revenue beat(2)N/A
Avg Revenue beat(2)N/A
Min Revenue beat(2)N/A
Max Revenue beat(2)N/A
Revenue beat(4)N/A
Avg Revenue beat(4)N/A
Min Revenue beat(4)N/A
Max Revenue beat(4)N/A
Revenue beat(8)N/A
Avg Revenue beat(8)N/A
Revenue beat(12)N/A
Avg Revenue beat(12)N/A
Revenue beat(16)N/A
Avg Revenue beat(16)N/A
PT rev (1m)0%
PT rev (3m)0%
EPS NQ rev (1m)-0.76%
EPS NQ rev (3m)-9.77%
EPS NY rev (1m)-0.86%
EPS NY rev (3m)-7.02%
Revenue NQ rev (1m)N/A
Revenue NQ rev (3m)N/A
Revenue NY rev (1m)N/A
Revenue NY rev (3m)N/A
Valuation
Industry RankSector Rank
PE N/A
Fwd PE N/A
P/S N/A
P/FCF N/A
P/OCF N/A
P/B 3.22
P/tB 3.22
EV/EBITDA N/A
EPS(TTM)-3.63
EYN/A
EPS(NY)-3.3
Fwd EYN/A
FCF(TTM)-2.04
FCFYN/A
OCF(TTM)-2.02
OCFYN/A
SpS0
BVpS2.06
TBVpS2.06
PEG (NY)N/A
PEG (5Y)N/A
Profitability
Industry RankSector Rank
ROA -63.99%
ROE -175.14%
ROCE N/A
ROIC N/A
ROICexc N/A
ROICexgc N/A
OM N/A
PM (TTM) N/A
GM N/A
FCFM N/A
ROA(3y)-52.31%
ROA(5y)-39.78%
ROE(3y)-97.26%
ROE(5y)-69.5%
ROIC(3y)N/A
ROIC(5y)N/A
ROICexc(3y)N/A
ROICexc(5y)N/A
ROICexgc(3y)N/A
ROICexgc(5y)N/A
ROCE(3y)N/A
ROCE(5y)N/A
ROICexcg growth 3YN/A
ROICexcg growth 5YN/A
ROICexc growth 3YN/A
ROICexc growth 5YN/A
OM growth 3YN/A
OM growth 5YN/A
PM growth 3YN/A
PM growth 5YN/A
GM growth 3YN/A
GM growth 5YN/A
F-Score4
Asset Turnover0
Health
Industry RankSector Rank
Debt/Equity 0
Debt/FCF N/A
Debt/EBITDA N/A
Cap/Depr 2.26%
Cap/Sales N/A
Interest Coverage N/A
Cash Conversion N/A
Profit Quality N/A
Current Ratio 4.62
Quick Ratio 4.62
Altman-Z -7.16
F-Score4
WACCN/A
ROIC/WACCN/A
Cap/Depr(3y)469.16%
Cap/Depr(5y)1839.16%
Cap/Sales(3y)N/A
Cap/Sales(5y)N/A
Profit Quality(3y)N/A
Profit Quality(5y)N/A
High Growth Momentum
Growth
EPS 1Y (TTM)18.06%
EPS 3YN/A
EPS 5YN/A
EPS Q2Q%-32.93%
EPS Next Y-19.48%
EPS Next 2Y0.91%
EPS Next 3Y3.29%
EPS Next 5Y8.89%
Revenue 1Y (TTM)N/A
Revenue growth 3YN/A
Revenue growth 5YN/A
Sales Q2Q%N/A
Revenue Next YearN/A
Revenue Next 2YN/A
Revenue Next 3YN/A
Revenue Next 5YN/A
EBIT growth 1Y20.42%
EBIT growth 3YN/A
EBIT growth 5YN/A
EBIT Next Year-10.92%
EBIT Next 3Y-22.55%
EBIT Next 5YN/A
FCF growth 1Y57.34%
FCF growth 3YN/A
FCF growth 5YN/A
OCF growth 1Y49.27%
OCF growth 3YN/A
OCF growth 5YN/A